Product (a.i.) (a.i. dose µg/ml) . | Strain . | Mean % mortality at time (min) after exposure . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
. | . | 5 . | 10 . | 15 . | 30 . | 45 . | 60 . | 75 . | 90 . | 105 . | 120 . |
Aqua-Reslin (Permethrin) (15) | Colony | NA | NA | 20.2 | 93.9 | 100 | 100 | 100 | 100 | 100 | 100 |
North | NA | NA | 15.4 | 52.2 | 63.7 | 92.8 | 90.4 | 94.4 | 95.2 | 96.0 | |
Lincoln | NA | NA | 14.7 | 73.1 | 89.6 | 92.5 | 95.4 | 96.4 | 97.5 | 96.9 | |
DeltaGard (Deltamethrin) (7) | Colony | 4.1 | 52.9 | 78.7 | 99.3 | 100 | 100 | 100 | 100 | 100 | 100 |
North | 4.0 | 26.9 | 71.6 | 97.6 | 96.2 | 97.6 | 96.0 | 97.0 | 99.4 | 99.2 | |
Lincoln | 3.5 | 39.6 | 72.7 | 94.9 | 94.6 | 97.9 | 100 | 98.7 | 100 | 99.3 | |
Scourge 18 + 54 (Resmethrin) (10) | Colony | 15.4 | 61.4 | 94.3 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
North | 2.3 | 9.4 | 30.6 | 50.7 | 68.9 | 68.9 | 74.9 | 78.7 | 80.3 | 80.2 | |
Lincoln | 9.1 | 10.0 | 13.1 | 44.8 | 56.7 | 50.2 | 85.4 | 85.4 | 87.9 | 90.5 |
Product (a.i.) (a.i. dose µg/ml) . | Strain . | Mean % mortality at time (min) after exposure . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
. | . | 5 . | 10 . | 15 . | 30 . | 45 . | 60 . | 75 . | 90 . | 105 . | 120 . |
Aqua-Reslin (Permethrin) (15) | Colony | NA | NA | 20.2 | 93.9 | 100 | 100 | 100 | 100 | 100 | 100 |
North | NA | NA | 15.4 | 52.2 | 63.7 | 92.8 | 90.4 | 94.4 | 95.2 | 96.0 | |
Lincoln | NA | NA | 14.7 | 73.1 | 89.6 | 92.5 | 95.4 | 96.4 | 97.5 | 96.9 | |
DeltaGard (Deltamethrin) (7) | Colony | 4.1 | 52.9 | 78.7 | 99.3 | 100 | 100 | 100 | 100 | 100 | 100 |
North | 4.0 | 26.9 | 71.6 | 97.6 | 96.2 | 97.6 | 96.0 | 97.0 | 99.4 | 99.2 | |
Lincoln | 3.5 | 39.6 | 72.7 | 94.9 | 94.6 | 97.9 | 100 | 98.7 | 100 | 99.3 | |
Scourge 18 + 54 (Resmethrin) (10) | Colony | 15.4 | 61.4 | 94.3 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
North | 2.3 | 9.4 | 30.6 | 50.7 | 68.9 | 68.9 | 74.9 | 78.7 | 80.3 | 80.2 | |
Lincoln | 9.1 | 10.0 | 13.1 | 44.8 | 56.7 | 50.2 | 85.4 | 85.4 | 87.9 | 90.5 |
Product (a.i.) (a.i. dose µg/ml) . | Strain . | Mean % mortality at time (min) after exposure . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
. | . | 5 . | 10 . | 15 . | 30 . | 45 . | 60 . | 75 . | 90 . | 105 . | 120 . |
Aqua-Reslin (Permethrin) (15) | Colony | NA | NA | 20.2 | 93.9 | 100 | 100 | 100 | 100 | 100 | 100 |
North | NA | NA | 15.4 | 52.2 | 63.7 | 92.8 | 90.4 | 94.4 | 95.2 | 96.0 | |
Lincoln | NA | NA | 14.7 | 73.1 | 89.6 | 92.5 | 95.4 | 96.4 | 97.5 | 96.9 | |
DeltaGard (Deltamethrin) (7) | Colony | 4.1 | 52.9 | 78.7 | 99.3 | 100 | 100 | 100 | 100 | 100 | 100 |
North | 4.0 | 26.9 | 71.6 | 97.6 | 96.2 | 97.6 | 96.0 | 97.0 | 99.4 | 99.2 | |
Lincoln | 3.5 | 39.6 | 72.7 | 94.9 | 94.6 | 97.9 | 100 | 98.7 | 100 | 99.3 | |
Scourge 18 + 54 (Resmethrin) (10) | Colony | 15.4 | 61.4 | 94.3 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
North | 2.3 | 9.4 | 30.6 | 50.7 | 68.9 | 68.9 | 74.9 | 78.7 | 80.3 | 80.2 | |
Lincoln | 9.1 | 10.0 | 13.1 | 44.8 | 56.7 | 50.2 | 85.4 | 85.4 | 87.9 | 90.5 |
Product (a.i.) (a.i. dose µg/ml) . | Strain . | Mean % mortality at time (min) after exposure . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
. | . | 5 . | 10 . | 15 . | 30 . | 45 . | 60 . | 75 . | 90 . | 105 . | 120 . |
Aqua-Reslin (Permethrin) (15) | Colony | NA | NA | 20.2 | 93.9 | 100 | 100 | 100 | 100 | 100 | 100 |
North | NA | NA | 15.4 | 52.2 | 63.7 | 92.8 | 90.4 | 94.4 | 95.2 | 96.0 | |
Lincoln | NA | NA | 14.7 | 73.1 | 89.6 | 92.5 | 95.4 | 96.4 | 97.5 | 96.9 | |
DeltaGard (Deltamethrin) (7) | Colony | 4.1 | 52.9 | 78.7 | 99.3 | 100 | 100 | 100 | 100 | 100 | 100 |
North | 4.0 | 26.9 | 71.6 | 97.6 | 96.2 | 97.6 | 96.0 | 97.0 | 99.4 | 99.2 | |
Lincoln | 3.5 | 39.6 | 72.7 | 94.9 | 94.6 | 97.9 | 100 | 98.7 | 100 | 99.3 | |
Scourge 18 + 54 (Resmethrin) (10) | Colony | 15.4 | 61.4 | 94.3 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
North | 2.3 | 9.4 | 30.6 | 50.7 | 68.9 | 68.9 | 74.9 | 78.7 | 80.3 | 80.2 | |
Lincoln | 9.1 | 10.0 | 13.1 | 44.8 | 56.7 | 50.2 | 85.4 | 85.4 | 87.9 | 90.5 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.